RMD
NYSEHealthcareLoading…
ResMed Inc. Common Stock
Sector: Healthcare•United States•Market Cap: $33.0B
Related News
Latest stories connected to RMD
- RS 73After Plunging 12.0% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)Zacks Investment Research•Mar 19, 2026•Original source
- RS 73ResMed (RMD) Upgraded to Buy: Here's What You Should KnowZacks Investment Research•Mar 17, 2026•Original source
- RS 73Is Resmed Stock the Right Pick for Your Portfolio Now?Zacks Investment Research•Mar 17, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B | 2.96B | 2.61B | 2.34B | 2.07B | 1.84B |
| Cost of Revenue | 2.09B | 2.03B | 1.87B | 1.55B | 1.36B | 1.24B | 1.07B | 978.03M | 864.99M | 772.22M |
| Gross Profit | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B | 1.72B | 1.54B | 1.36B | 1.20B | 1.07B |
| Research and Development Expenses | 331.28M | 307.52M | 287.64M | 253.57M | 225.28M | 201.95M | 180.65M | 155.15M | 144.47M | 118.65M |
| General and Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 600.37M | 553.97M | 488.06M |
| Selling and Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General and Administrative Expenses | 991.02M | 917.14M | 874.00M | 739.37M | 670.39M | 676.69M | 645.01M | 600.37M | 553.97M | 488.06M |
| Other Expenses | 47.30M | 110.75M | 62.15M | 31.08M | 39.75M | 30.09M | 131.66M | 64.81M | 77.51M | 30.84M |
| Operating Expenses | 1.37B | 1.34B | 1.22B | 1.02B | 935.42M | 908.73M | 957.32M | 820.33M | 775.95M | 637.54M |
| Cost and Expenses | 3.46B | 3.37B | 3.09B | 2.58B | 2.29B | 2.15B | 2.03B | 1.80B | 1.64B | 1.41B |
| Net Interest Income | -12.61M | -45.71M | -47.38M | -22.31M | -23.63M | -39.36M | -33.86M | -11.98M | -11.15M | 5.65M |
| Interest Income | 0 | 0 | 0 | 0 | 362.00K | 1.02M | 2.30M | 16.38M | 17.09M | 16.86M |
| Interest Expense | 12.61M | 45.71M | 47.38M | 22.31M | 23.99M | 40.38M | 36.16M | 28.36M | 28.24M | 11.21M |
| Depreciation and Amortization | 235.81M | 216.21M | 197.56M | 193.84M | 191.52M | 181.37M | 150.79M | 119.96M | 112.16M | 86.85M |
| EBITDA | 1.91B | 1.53B | 1.36B | 1.18B | 1.10B | 990.43M | 705.80M | 680.22M | 568.89M | 522.72M |
| EBIT | 1.68B | 1.31B | 1.16B | 982.79M | 912.35M | 809.06M | 555.00M | 560.26M | 456.73M | 435.87M |
| Non Operating Income Excluding Interest | 9.83M | 9.39M | -30.41M | 17.49M | -8.67M | 600.00K | 24.26M | -18.43M | -30.93M | -6.91M |
| Operating Income | 1.69B | 1.32B | 1.13B | 1.00B | 903.68M | 809.66M | 579.26M | 541.83M | 425.80M | 428.95M |
| Total Other Income Expenses Net | -7.80M | -55.09M | -30.21M | -39.80M | -20.02M | -76.57M | -60.42M | -20.52M | -7.05M | 10.61M |
| Income Before Tax | 1.68B | 1.26B | 1.10B | 960.48M | 883.66M | 733.09M | 518.85M | 521.31M | 418.74M | 439.56M |
| Income Tax Expense | 276.84M | 243.85M | 204.11M | 181.05M | 409.16M | 111.41M | 114.25M | 205.72M | 76.46M | 87.16M |
| Net Income From Continuing Operations | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M | 315.59M | 342.28M | 352.41M |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M | 315.59M | 342.28M | 352.41M |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 9.55 | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 | 2.51 |
| EPS Diluted | 9.51 | 6.92 | 6.09 | 5.3 | 3.24 | 4.27 | 2.8 | 2.19 | 2.4 | 2.49 |
| Weighted Average SHS Out | 146.72M | 147.02M | 146.76M | 146.07M | 145.31M | 144.34M | 143.11M | 142.76M | 141.36M | 140.24M |
| Weighted Average SHS Out Dil | 147.34M | 147.55M | 147.46M | 147.04M | 146.45M | 145.65M | 144.48M | 143.99M | 142.45M | 141.67M |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.59 | 0.57 | 0.56 | 0.57 | 0.58 | 0.58 | 0.59 | 0.58 | 0.58 | 0.58 |
| R&D to Revenue | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 |
| SG&A to Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.26 | 0.27 | 0.27 |
| Interest Burden | 1 | 0.97 | 0.95 | 0.98 | 0.97 | 0.91 | 0.93 | 0.93 | 0.92 | 1.01 |
| EBIT Margin | 0.33 | 0.28 | 0.28 | 0.27 | 0.29 | 0.27 | 0.21 | 0.24 | 0.22 | 0.24 |
| EBITDA Margin | 0.37 | 0.33 | 0.32 | 0.33 | 0.35 | 0.33 | 0.27 | 0.29 | 0.28 | 0.28 |
| EBT per EBIT | 1 | 0.96 | 0.97 | 0.96 | 0.98 | 0.91 | 0.9 | 0.96 | 0.98 | 1.02 |
| Effective Tax Rate | 0.17 | 0.19 | 0.19 | 0.19 | 0.46 | 0.15 | 0.22 | 0.39 | 0.18 | 0.2 |
| Tax Burden | 0.83 | 0.81 | 0.81 | 0.81 | 0.54 | 0.85 | 0.78 | 0.61 | 0.82 | 0.8 |
| Cont. Operations Profit Margin | 0.27 | 0.22 | 0.21 | 0.22 | 0.15 | 0.21 | 0.16 | 0.13 | 0.17 | 0.19 |
| Bottom Line Profit Margin | 0.27 | 0.22 | 0.21 | 0.22 | 0.15 | 0.21 | 0.16 | 0.13 | 0.17 | 0.19 |
| Operating Cycle | 232.17 | 213.07 | 256 | 233.5 | 193 | 181.39 | 193.28 | 175.72 | 192.79 | 181.94 |
| Fwd PEG Ratio | 0.72 | 2.01 | 2.45 | 0.62 | -3.13 | 0.85 | 1.56 | -5.4 | -8.97 | 0 |
| Earnings Yield | 0.04 | 0.04 | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 |
| Income Quality | 1.25 | 1.37 | 0.77 | 0.45 | 1.55 | 1.29 | 1.13 | 1.6 | 1.21 | 1.55 |